MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is 18 years of age or older
- Patient has had a history of migraine with or without aura
- Patient is able to complete study questionnaire(s) and paper diary
Exclusion Criteria:
- Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of the study
- Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions
- Patient was older than 50 years of age at migraine onset
- History of gastric or small intestinal surgery or has a disease that causes malabsorption
- Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study
- Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study
- Currently participating in a study with MK-0974 or MK-3207
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Telcagepant 140 mg
Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
|
Other Names:
|
|
Experimental: Telcagepant 280 mg
Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
|
Other Names:
|
|
Placebo Comparator: Placebo
Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Mean Monthly Headache Days
Time Frame: Baseline and Week 12
|
Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed.
This information was used to determine the mean monthly headache days; a headache day was defined as any day in which a qualified headache (>=30 minute duration or requiring acute treatment) started, ended, or recurred.
Headache pain persisting for more than 1 calendar day after initial onset was considered an occurrence of multiple distinct headache days.
Mean monthly rate was adjusted to 28 days.
|
Baseline and Week 12
|
|
Change From Baseline in Mean Monthly Migraine Days
Time Frame: Baseline and Week 12
|
Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed.
This information was used to determine the mean monthly migraine days; a migraine day was defined as any day in which a qualified headache( i.e., aura, photophobia, phonophobia, nausea, or vomiting) started, ended, or recurred.
Migraine pain persisting for more than 1 calendar day after initial onset was considered an occurrence of multiple distinct migraine days.
Mean monthly rate was adjusted to 28 days.
|
Baseline and Week 12
|
|
Percentage of Participants Who Experienced an Adverse Event
Time Frame: up to 14 days after last dose of study drug (up to 12 weeks)
|
Participants were assessed throughout the study for adverse events and recorded adverse events in a daily dairy.
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an adverse event.
|
up to 14 days after last dose of study drug (up to 12 weeks)
|
|
Percentage of Participants Who Had Study Drug Discontinued During the Study Due to an Adverse Event
Time Frame: up to 12 weeks
|
Participants were assessed throughout the study for adverse events and recorded adverse events in a daily dairy.
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an adverse event.
The percentage of participants who discontinued study was summarized.
|
up to 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With at Least a 50% Reduction in Mean Monthly Headache Days
Time Frame: Week 12
|
Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed.
This information was used to determine the mean monthly headache days; a headache day was defined as any day in which a qualified headache (>=30 minute duration or requiring acute treatment) started, ended, or recurred.
Headache pain persisting for more than 1 calendar day after initial onset was considered an occurrence of multiple distinct headache days.
Mean monthly rate was adjusted to 28 days.
The percentage of participants who had at least a 50% reduction in mean monthly headache days during the 12 weeks treatment period was summarized
|
Week 12
|
|
Change From Baseline in the Mean Monthly Migraine Attacks
Time Frame: Baseline and Week 12
|
Participants entered information about the number of migraine headaches, symptoms, headache pain duration and severity, use of medication, and side effects into a diary each evening just before going to bed.
This information was used to determine the mean monthly migraine days; a migraine day was defined as any day in which a qualified headache was accompanied with associated symptoms.(
i.e., aura, photophobia, phonophobia, nausea, or vomiting) started, ended, or recurred.
A migraine attack was defined as any migraine headache that occurs within 2 consecutive calendar days.
Pain persisting for more than 2 days after its initial onset was considered a new, distinct migraine attack.
The number of migraine attacks that occurred per month was calculated.
Mean monthly rate was adjusted to 28 days.
|
Baseline and Week 12
|
|
Change From Baseline in the Mean Number of Days Per Month Requiring Rescue Medication
Time Frame: Baseline and Week 12
|
Participants completed a diary each evening just before going to bed.
Information recorded included: date of assessment, administration of study medication, medication to treat breakthrough migraines and other headaches, associated symptoms, duration of headache pain, headache severity, and side effects.
Participants use of medication to treat a breakthrough migraine/headache was considered rescue medication.
The number of days per month requiring rescue medication was calculated.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0974-049
- 2008_591
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.